Get the Stockscreener App
1.99
4.74%
0.09
Pre-market:
2.11
0.12
+6.03%
Palisade Bio Inc stock is traded at $1.99, with a volume of 5.82M.
It is up +4.74% in the last 24 hours and up +4.74% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$1.90
Open:
$1.97
24h Volume:
5.82M
Relative Volume:
1.05
Market Cap:
$296.91M
Revenue:
-
Net Income/Loss:
$-14.07M
P/E Ratio:
-0.1422
EPS:
-13.99
Net Cash Flow:
$-12.56M
1W Performance:
-20.40%
1M Performance:
+4.74%
6M Performance:
+161.84%
1Y Performance:
-1.00%
1-Day Range:
$1.86
$2.03
1-Week Range:
$1.845
$2.55
52-Week Range:
$0.53
$2.64
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
1.99 | 283.49M | 0 | -14.07M | -12.56M | -13.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-09-26 | Initiated | B. Riley Securities | Buy |
| Dec-29-25 | Initiated | Piper Sandler | Overweight |
Palisade Bio Inc Stock (PALI) Latest News
Palisade Bio (PALI) soars 5% ahead of clinical trial results - MSN
Short Covering: Is Palisade Bio Inc stock a dividend growth opportunity2025 Trading Volume Trends & Consistent Profit Focused Trading Strategies - moha.gov.vn
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Palisade Bio (PALI) upgraded to buy: Here's what you should know - MSN
PALI: B. Riley Securities Initiates Coverage with 'Buy' Rating | - GuruFocus
B.Riley initiates coverage on Palisade Bio stock with Buy rating By Investing.com - Investing.com Nigeria
B.Riley initiates coverage on Palisade Bio stock with Buy rating - Investing.com Australia
How Palisade Bio Inc. (7NS0) stock reacts to Fed tighteningShort Setup & Consistent Profit Trading Strategies - ulpravda.ru
Can Palisade Bio Inc. stock deliver consistent earnings growthTrade Risk Report & Expert Approved Momentum Ideas - ulpravda.ru
What is the fair value of Palisade Bio Inc. stock nowEarnings Growth Summary & Verified Momentum Stock Ideas - ulpravda.ru
Crohn’s & Colitis Foundation invests up to $500,000 in Palisade Bio By Investing.com - Investing.com Nigeria
How currency fluctuations impact Palisade Bio Inc. stockEx-Dividend Date Alerts & Low Entry Cost Investment - ulpravda.ru
Exit Recap: Will Palisade Bio Inc stock attract more institutional investors2025 AllTime Highs & High Conviction Buy Zone Alerts - moha.gov.vn
Palisade Bio Announces Strategic Investment from Crohn's & Colitis Foundation to Support Development of PALI-2108 for Ulcerative Colitis and Crohn's Disease - Quiver Quantitative
Crohn’s & Colitis Foundation backs new gut-targeted drug for severe IBD - Stock Titan
Will Palisade Bio Inc. stock benefit from sector rotationStability vs Neutral Overview & HOKA buying tips before checkout - ulpravda.ru
Wall Street Zen Upgrades Palisade Bio (NASDAQ:PALI) to "Hold" - MarketBeat
Risk Report: What is the fair value of Palisade Bio Inc stock now2025 Major Catalysts & Intraday High Probability Setup Alerts - moha.gov.vn
Analysts Are Bullish on These Healthcare Stocks: Palisade Bio (PALI), Centessa Pharmaceuticals (CNTA) - The Globe and Mail
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Palisade Bio (NASDAQ:PALI) Stock Rating Upgraded by Clear Str - MarketBeat
9,119,152 Common Stock of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - MarketScreener
Certain Stock Options of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Certain Restricted Stock Units of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Certain Warrants of Palisade Bio, Inc. are subject to a Lock-Up Agreement Ending on 31-DEC-2025. - marketscreener.com
Palisade Bio receives patent approval in Japan for IBD drug PALI-2108 - Investing.com Nigeria
Palisade Bio Says Japan Grants Patent for Composition of PALI-2108 - MarketScreener
Palisade Bio receives patent approval in Japan for IBD drug PALI-2108 By Investing.com - Investing.com South Africa
New gut-targeted drug gains key patent in Japan for severe bowel disease - Stock Titan
Palisade Bio (NASDAQ:PALI) Upgraded at Piper Sandler - MarketBeat
Palisade Bio Announces Granting of Japanese Patent Covering Composition of Matter for Lead Product Candidate, PALI-2108 - The Manila Times
Palisade Bio stock initiated with Buy rating at Clear Street on IBD drug potential - Investing.com
Palisade Bio Appoints New VP to Drive Further Growth - StocksToTrade
DigitalBridge Group, Eightco Holdings, Palisade Bio And Other Big Stocks Moving Higher On Monday - Benzinga
PALI’s Strategic Move: What’s Next? - timothysykes.com
Piper Sandler initiates Palisade Bio stock with Overweight rating on IBD drug By Investing.com - Investing.com Nigeria
Piper Sandler initiates Palisade Bio stock with Overweight rating on IBD drug - Investing.com
Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results - Finviz
10 Stocks Lighting Up Market Ahead of Christmas - Insider Monkey
Palisade Bio: Gut Prodrug For IBD With Catalysts - Seeking Alpha
Aug Summary: Is Palisade Bio Inc stock ready for breakout2025 Macro Impact & AI Enhanced Market Trend Forecasts - moha.gov.vn
Published on: 2025-12-21 10:03:36 - Улправда
Why analysts remain bullish on Palisade Bio Inc. stock2025 Top Gainers & High Accuracy Investment Signals - Улправда
What earnings margins imply for Palisade Bio Inc. (7NS0) stockPortfolio Gains Summary & Weekly Top Stock Performers List - Улправда
Palisade Bio (NASDAQ:PALI) Stock Rating Lowered by Wall Street Zen - MarketBeat
Can Palisade Bio Inc. stock deliver surprise earnings beatWatch List & High Return Stock Watch Alerts - Улправда
How Palisade Bio Inc. stock reacts to bond yields2025 Performance Recap & Daily Entry Point Trade Alerts - Улправда
Is Palisade Bio Inc. stock a good choice for value investorsJuly 2025 Pullbacks & Low Risk Investment Opportunities - Улправда
Palisade Bio (PALI) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Aug Macro: How geopolitical risks impact Palisade Bio Inc. (7NS0) stock2025 Support & Resistance & Free High Accuracy Swing Entry Alerts - Улправда
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):